Published 6 issues per year
ISSN Print: 1045-4403
ISSN Online: 2162-6502
Indexed in
Nucleic Acid Modulation of Gene Expression: Approaches for Nucleic Acid Therapeutics Against Cancer
ABSTRACT
Most cancers are characterized by abnormal gene expression, which is thought to contribute to the pathogenesis and maintenance of the malignant phenotype; abnormal proliferation, maturation, and apoptosis. Silencing such genes would appear to be a rational approach to the therapy of cancer, and some preliminary clinical studies support this concept. Of the strategies available, the anti-mRNA gene silencing approach has attracted much attention and is the focus of this review. This strategy includes three types of agents: (1) single-stranded antisense oligonucleotides; (2) catalytically active oligonucleotides, such as ribozymes, and DNAzymes that possess inherent RNA cleaving activity; and (3) small interfering RNA (siRNA) molecules that induce RNA interference (RNAi). Among these agents, antisense oligonucleotides, especially phosphorothioate (PS) oligonucleotides, have been the most frequently used in clinical trials. In this article, we provide an overview of anti-mRNA gene silencing agents and their development for use as cancer therapeutics.
-
Chonco Louis, Bermejo-Martín Jesus F., Ortega Paula, Shcharbin Dzmitry, Pedziwiatr Elzbieta, Klajnert Barbara, Javier de la Mata F., Eritja Ramon, Gómez Rafael, Bryszewska Maria, Angeles Muñoz-Fernandez Ma, Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins, Org. Biomol. Chem., 5, 12, 2007. Crossref
-
Papsai Pal, Aldag Jasmin, Persson Tina, Elmroth Sofi K. C., Kinetic preference for interaction of cisplatin with the G–C-rich wobble basepair region in both tRNAAlaand MhAla, Dalton Trans., 29, 2006. Crossref
-
Schiffelers Raymond M, Storm Gert, ICS-283: a system for targeted intravenous delivery of siRNA, Expert Opinion on Drug Delivery, 3, 3, 2006. Crossref
-
Li Jing, Zhu Zhenping, Research and development of next generation of antibody-based therapeutics, Acta Pharmacologica Sinica, 31, 9, 2010. Crossref
-
Toub Nedjma, Bertrand Jean-Rémi, Malvy Claude, Fattal Elias, Couvreur Patrick, Antisense Oligonucleotide Nanocapsules Efficiently Inhibit EWS-Fli1 Expression in a Ewing's Sarcoma Model, Oligonucleotides, 16, 2, 2006. Crossref
-
Fuessel Susanne, Meye Axel, Kraemer Kai, Kunze Doreen, Hakenberg Oliver W., Wirth Manfred P., Synthetic Nucleic Acids as Potential Therapeutic Tools for Treatment of Bladder Carcinoma, European Urology, 51, 2, 2007. Crossref
-
Pershouse Mark A., Heivly Shane, Girtsman Teri, The Role of SV40 in Malignant Mesothelioma and Other Human Malignancies, Inhalation Toxicology, 18, 12, 2006. Crossref
-
Niewiarowska J, Sacewicz I, Wiktorska M, Wysocki T, Stasikowska O, Wagrowska-Danilewicz M, Cierniewski C S, DNAzymes to mouse β1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth, Cancer Gene Therapy, 16, 9, 2009. Crossref